Surgery
Volume 146, Issue 6 , Pages 1196-1207 , December 2009

A novel HSP90 modulator with selective activity against thyroid cancers in vitro

  • Abbas Samadi, PhD

      Affiliations

    • Department of Surgery, University of Kansas Medical Center, Kansas City, KS
    • ,
  • Peter Loo, BS

      Affiliations

    • Department of Surgery, University of Kansas Medical Center, Kansas City, KS
    • ,
  • Rithwi Mukerji, MD

      Affiliations

    • Department of Surgery, University of Kansas Medical Center, Kansas City, KS
    • ,
  • Gemma O'Donnell, PhD

      Affiliations

    • Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS
    • ,
  • Xiaqin Tong, MS

      Affiliations

    • Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS
    • ,
  • Barbara N. Timmermann, PhD

      Affiliations

    • Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS
    • ,
  • Mark S. Cohen, MD, FACS

      Affiliations

    • Department of Surgery, University of Kansas Medical Center, Kansas City, KS
    • Corresponding Author InformationReprint requests: Mark S. Cohen, MD, FACS, Vice Chairman for Research, Department of Surgery, University of Kansas Medical Center, 2035 Sutherland Institute, Mail Stop 2005, 3901Rainbow Boulevard, Kansas City, KS 66160.

References 

  1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society; 2008: 5. Available from URL: www.cancer.org.
  2. Randolph GW, Thompson GB, Branovan DI, Tuttle RM. Treatment of thyroid cancer: 2007—a basic review. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S92–S99
  3. Sanders EM, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31:934–945
  4. Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab. 2006;2:42-52
  5. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–262
  6. Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab. 2006;2:180–181
  7. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161–1170
  8. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett. 2006;232:90–98
  9. Santoro M, Fusco A. New drugs in thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51:857–861
  10. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306
  11. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32
  12. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199–10207
  13. Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev. 2006;26:310–338
  14. Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008;8:761–782
  15. Yokota Y, Bargagna-Mohan P, Ravindranath PP, Kim KB, Mohan R. Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett. 2006;16:2603–2607
  16. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5:334–346
  17. Yu XM, Shen G, Neckers L, et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc. 2005;127:12778–12779
  18. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32:517–530
  19. Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol. 2007;14:1204–1206
  20. Chaudhury S, Welch TR, Blagg BS. Hsp90 as a target for drug development. ChemMedChem. 2006;1:1331–1340
  21. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007;98:1536–1539
  22. Chiosis G, Huezo H, Rosen N, et al. 17AAG: low target binding affinity and potent cell activity—finding an explanation. Mol Cancer Ther. 2003;2:123–129
  23. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer—present and future. Curr Cancer Drug Targets. 2003;3:385–390
  24. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 2003;3:377–383
  25. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331–4341

 Presented at the 30th Annual Meeting of the American Association of Endocrine Surgeons, Madison, Wisconsin, May 2–5, 2009.

 Supported in part by research grants from the National Institutes of Health (P20 RR016443 to B.N.T. and M.S.C.) through the University of Kansas Center for Cancer Experimental Therapeutics (CCET) National Institutes of Health Center of Biomedical Research Excellence (COBRE) Program.

PII: S0039-6060(09)00569-8

doi: 10.1016/j.surg.2009.09.028

Surgery
Volume 146, Issue 6 , Pages 1196-1207 , December 2009

Article Tools

* Image Usage & Resolution